Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

Enhanced fatty acid oxidation in adipocytes and macrophages reduces lipid-induced triglyceride accumulation and inflammation

  • Malandrino, Maria Ida
  • Fucho Salvador, Raquel
  • Weber Blattes, Minéia
  • Calderón Domínguez, María
  • Mir Bonnín, Joan Francesc
  • Valcarcel Jimenez, Lorea
  • Escoté, Xavier
  • Gómez-Serrano, María
  • Peral, Belén
  • Salvadó Serra, Laia
  • Casals i Farré, Núria
  • Villarroya i Gombau, Francesc
  • Vázquez Carrera, Manuel
  • Vendrell, Joan
  • Serra i Cucurull, Dolors
  • Herrero Rodríguez, Laura
Lipid overload in obesity and type 2 diabetes is associated with adipocyte dysfunction, inflammation, macrophage infiltration, and decreased fatty acid oxidation (FAO). Here, we report that the expression of carnitine palmitoyltransferase 1A (CPT1A), the rate-limiting enzyme in mitochondrial FAO, is higher in human adipose tissue macrophages than in adipocytes and that it is differentially expressed in visceral vs. subcutaneous adipose tissue in both an obese and a type 2 diabetes cohort. These observations led us to further investigate the potential role of CPT1A in adipocytes and macrophages. We expressed CPT1AM, a permanently active mutant form of CPT1A, in 3T3-L1 CARΔ1 adipocytes and RAW 264.7 macrophages through adenoviral infection. Enhanced FAO in palmitate-incubated adipocytes and macrophages reduced triglyceride content and inflammation, improved insulin sensitivity in adipocytes, and reduced endoplasmic reticulum stress and ROS damage in macrophages. We conclude that increasing FAO in adipocytes and macrophages improves palmitate-induced derangements. This indicates that enhancing FAO in metabolically relevant cells such as adipocytes and macrophages may be a promising strategy for the treatment of chronic inflammatory pathologies such as obesity and type 2 diabetes.
Dipòsit Digital de la UB
Publicación Artículo científico (JournalArticle)

FGF21 and cardiac Physiopathology

  • Planavila Porta, Ana
  • Redondo Angulo, Ibon
  • Villarroya i Gombau, Francesc
The heart is not traditionally considered either a target or a site of fibroblast growth factor-21 (FGF21) production. However, recent findings indicate that FGF21 can act as a cardiomyokine; that is, it is produced by cardiac cells at significant levels and acts in an autocrine manner on the heart itself. The heart is sensitive to the effects of FGF21, both systemic and locally generated, owing to the expression in cardiomyocytes of β-Klotho, the key co-receptor known to confer specific responsiveness to FGF21 action. FGF21 has been demonstrated to protect against cardiac hypertrophy, cardiac inflammation, and oxidative stress. FGF21 expression in the heart is induced in response to cardiac insults, such as experimental cardiac hypertrophy and myocardial infarction in rodents, as well as in failing human hearts. Intracellular mechanisms involving PPARα and Sirt1 mediate transcriptional regulation of the FGF21 gene in response to exogenous stimuli. In humans, circulating FGF21 levels are elevated in coronary heart disease and atherosclerosis, and are associated with a higher risk of cardiovascular events in patients with type 2 diabetes. These findings provide new insights into the role of FGF21 in the heart and may offer potential therapeutic strategies for cardiac disease.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Peroxisome proliferator-activated receptors-α and -γ and cAMP-mediated pathways, control retinol-binding protein-4 gene expression in brown adipose tissue

  • Rosell, Meritxell
  • Hondares, Elayne
  • Monsalve, María
  • Giralt, Marta
  • Iglesias, Roser
  • Villaroya, Francesc
12 páginas, 7 figuras, 1 tabla.-- et al., Retinol binding protein-4 (RBP4) is a serum protein involved in the transport of vitamin A. It is known to be produced by the liver and white adipose tissue. RBP4 release by white fat has been proposed to induce insulin resistance. We analyzed the regulation and production of RBP4 in brown adipose tissue. RBP4 gene expression is induced in brown fat from mice exposed to cold or treated with peroxisome proliferator-activated receptor (PPAR) agonists. In brown adipocytes in culture, norepinephrine, cAMP, and activators of PPARγ and PPARα induced RBP4 gene expression and RBP4 protein release. The induction of RBP4 gene expression by norepinephrine required intact PPAR-dependent pathways, as evidenced by impaired response of the RBP4 gene expression to norepinephrine in PPARα-null brown adipocytes or in the presence of inhibitors of PPARγ and PPARα. PPARγ and norepinephrine can also induce the RBP4 gene in white adipocytes, and over expression of PPARα confers regulation by this PPAR subtype to white adipocytes. The RBP4 gene promoter transcription is activated by cAMP, PPARα, and PPARγ. This is mediated by a PPAR-responsive element capable of binding PPARα and PPARγ and required also for activation by cAMP. The induction of the RBP4 gene expression by norepinephrine in brown adipocytes is protein synthesis dependent and requires PPARα-coactivator- 1-α, which acts as a norepinephine-induced coactivator of PPAR on the RBP4 gene. We conclude that PPARγ- and PPARγ-mediated signaling controls RBP4 gene expression and releases in brown adipose tissue, and thermogenic activation induces RBP4 gene expression in brown fat through mechanisms involving PPARγ-coactivator-1-α coactivation of PPAR signaling. Copyright © 2012 by The Endocrine Society., This work was supported by the Ministerio de Ciencia e Innovación Grant SAF2008-01896, SAF2011-23636 and Fondo de Investigaciones Sanitarias Grant PI081715, Spain. Centro de Investigación Biomédica en Red Fisiopatologia de la Obesidad y Nutrición is an initiative of Instituto de Salud Carlos III Spain, and Grant HEALTH-F2-2011-277713 by the European Union., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Enhanced fatty acid oxidation in adipocytes and macrophages reduces lipid-induced triglyceride accumulation and inflammation

  • Calderón‐Domínguez, María
  • Escoté, Xavier
  • Gómez-Serrano, María
  • Peral, Belén
  • Fernández-Veledo, Sonia
  • Vázquez-Carrera, Manuel
  • Villaroya, Francesc
  • Vendrell, Joan
  • Herrero, Laura
Lipid overload in obesity and type 2 diabetes is associated with adipocyte dysfunction, inflammation, macrophage infiltration, and decreased fatty acid oxidation (FAO). Here, we report that the expression of carnitine palmitoyltransferase 1A (CPT1A), the rate-limiting enzyme in mitochondrial FAO, is higher in human adipose tissue macrophages than in adipocytes and that it is differentially expressed in visceral vs. subcutaneous adipose tissue in both an obese and a type 2 diabetes cohort. These observations led us to further investigate the potential role of CPT1A in adipocytes and macrophages. We expressed CPT1AM, a permanently active mutant form of CPT1A, in 3T3-L1 CAR¿1 adipocytes and RAW 264.7 macrophages through adenoviral infection. Enhanced FAO in palmitate-incubated adipocytes and macrophages reduced triglyceride content and inflammation, improved insulin sensitivity in adipocytes, and reduced endoplasmic reticulum stress and ROS damage in macrophages. We conclude that increasing FAO in adipocytes and macrophages improves palmitate-induced derangements. This indicates that enhancing FAO in metabolically relevant cells such as adipocytes and macrophages may be a promising strategy for the treatment of chronic inflammatory pathologies such as obesity and type 2 diabetes., This study was supported by the Spanish Ministry of Science and Innovation (Grants SAF2010-20039 and SAF2013-45887-R to L. Herrero, SAF2011-30520-C02-01 to D. Serra, PI11/00085 to J. J. Vendrell, SAF2012-33014 to B. Peral, SAF2012-36186 to S. Fernández-Veledo, SAF2012-30708 to M. Vázquez-Carrera, SAF2011-23626 to F. Villarroya, and doctoral fellowships to M. I. Malandrino and J. F. Mir), by the CIBER Fisiopatología de la Obesidad y la Nutrición (Grant CB06/03/0001 to D. Serra), and CIBER Diabetes y Enfermedades Metabólicas Asociadas (Grant CB07/08/0003 to M. Vázquez-Carrera), Instituto de Salud Carlos III, by the European Union (BetaBat project FP7-277713 to F. Villarroya), by the European Foundation for the Study of Diabetes (EFSD)/Lilly and EFSD/Janssen-Rising Star research fellowships to L. Herrero, and by a L’Oréal-UNESCO “For Women in Science” research fellowship to L. Herrero. S. Fernández-Veledo acknowledges support from the “Miguel Servet” tenure track program (CP10/00438) from the Fondo de Investigación Sanitaria and cofinanced by the European Regional Development Fund. M. Weber is a recipient of the Ciência sem Fronteiras-CNPq fellowship (237976/2012-9)., Peer Reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

FGF21 and cardiac Physiopathology

  • Planavila Porta, Ana
  • Redondo Angulo, Ibon
  • Villarroya i Gombau, Francesc
The heart is not traditionally considered either a target or a site of fibroblast growth factor-21 (FGF21) production. However, recent findings indicate that FGF21 can act as a cardiomyokine; that is, it is produced by cardiac cells at significant levels and acts in an autocrine manner on the heart itself. The heart is sensitive to the effects of FGF21, both systemic and locally generated, owing to the expression in cardiomyocytes of β-Klotho, the key co-receptor known to confer specific responsiveness to FGF21 action. FGF21 has been demonstrated to protect against cardiac hypertrophy, cardiac inflammation, and oxidative stress. FGF21 expression in the heart is induced in response to cardiac insults, such as experimental cardiac hypertrophy and myocardial infarction in rodents, as well as in failing human hearts. Intracellular mechanisms involving PPARα and Sirt1 mediate transcriptional regulation of the FGF21 gene in response to exogenous stimuli. In humans, circulating FGF21 levels are elevated in coronary heart disease and atherosclerosis, and are associated with a higher risk of cardiovascular events in patients with type 2 diabetes. These findings provide new insights into the role of FGF21 in the heart and may offer potential therapeutic strategies for cardiac disease.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Enhanced fatty acid oxidation in adipocytes and macrophages reduces lipid-induced triglyceride accumulation and inflammation

  • Malandrino, Maria Ida
  • Fucho Salvador, Raquel
  • Weber Blattes, Minéia
  • Calderón Domínguez, María
  • Mir Bonnín, Joan Francesc
  • Valcarcel Jimenez, Lorea
  • Escoté, Xavier
  • Gómez-Serrano, María
  • Peral, Belén
  • Salvadó Serra, Laia
  • Casals i Farré, Núria
  • Villarroya i Gombau, Francesc
  • Vázquez Carrera, Manuel
  • Vendrell, Joan
  • Serra i Cucurull, Dolors
  • Herrero Rodríguez, Laura
Lipid overload in obesity and type 2 diabetes is associated with adipocyte dysfunction, inflammation, macrophage infiltration, and decreased fatty acid oxidation (FAO). Here, we report that the expression of carnitine palmitoyltransferase 1A (CPT1A), the rate-limiting enzyme in mitochondrial FAO, is higher in human adipose tissue macrophages than in adipocytes and that it is differentially expressed in visceral vs. subcutaneous adipose tissue in both an obese and a type 2 diabetes cohort. These observations led us to further investigate the potential role of CPT1A in adipocytes and macrophages. We expressed CPT1AM, a permanently active mutant form of CPT1A, in 3T3-L1 CARΔ1 adipocytes and RAW 264.7 macrophages through adenoviral infection. Enhanced FAO in palmitate-incubated adipocytes and macrophages reduced triglyceride content and inflammation, improved insulin sensitivity in adipocytes, and reduced endoplasmic reticulum stress and ROS damage in macrophages. We conclude that increasing FAO in adipocytes and macrophages improves palmitate-induced derangements. This indicates that enhancing FAO in metabolically relevant cells such as adipocytes and macrophages may be a promising strategy for the treatment of chronic inflammatory pathologies such as obesity and type 2 diabetes.